Melanoma prognostic model using tissue microarrays and genetic algorithms

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5772-5780

  Gould Rothberg, Bonnie E ^a   Berger, Aaron J ^a   Molinaro, Annette M ^a   Subtil, Antonio ^a   Krauthammer, Michael O ^a   Camp, Robert L ^a   Bradley, William R ^a   Ariyan, Stephan ^a   Kluger, Harriet M ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBRONECTIN; ACTIVATING TRANSCRIPTION FACTOR 2; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ALGORITHM; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENTINEL LYMPH NODE; TISSUE MICROARRAY; ALGORITHM; CHEMISTRY; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROTEIN MICROARRAY; SKIN TUMOR; SURVIVAL RATE;

ACTIVATING TRANSCRIPTION FACTOR 2; ALGORITHMS; BETA CATENIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SKIN NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73349128764     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.8239     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998-1012, 2004
3. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
4. Gimotty PA, Elder DE, Fraker DL, et al: Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25:1129-1134, 2007
5. Taylor C: Standardization in immunohistochemistry: The role of antigen retrieval in molecular morphology. Biotech Histochem 81:3-12, 2006
6. Gimotty PA, Van Belle P, Elder DE, et al: Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23:8048-8056, 2005
7. Gould Rothberg BE, Bracken MB, Rimm DL: Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 101:452-474, 2009
8. Ariyan S, Ariyan C, Farber LR, et al: Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma. J Am Coll Surg 198:924-932, 2004
9. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
10. Kreizenbeck GM, Berger AJ, Subtil A, et al: Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 17:949-958, 2008
11. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327, 2002
12. Mitchell M: An Introduction to Genetic Algorithms. Cambridge, MA, MIT Press, 1998
13. Ooi CH, Tan P: Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics 19:37-44, 2003
14. Camp RL, Dolled-Filhart M, Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252-7259, 2004
15. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184, 2005
16. Gimotty PA, Botbyl J, Soong SJ, et al: A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 23:8065-8075, 2005
17. Winnepenninckx V, Lazar V, Michiels S, et al: Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-482, 2006
18. Viros A, Fridlyand J, Bauer J, et al: Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5:e120, 2008
19. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406:536-540, 2000
20. Alonso SR, Ortiz P, Pollan M, et al: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study. Am J Pathol 164:193-203, 2004
21. Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6:1845-1853, 2000
22. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999
23. Evangelou K, Bramis J, Peros I, et al: Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact: A study in non-small cell lung carcinomas. Biotech Histochem 79:5-10, 2004
24. Keller-Melchior R, Schmidt R, Piepkorn M: Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 110:932-938, 1998
25. Sauroja I, Smeds J, Vlaykova T, et al: Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 28:404-414, 2000
26. Maelandsmo GM, Holm R, Fodstad O, et al: Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: Reduced expression in metastatic lesions. Am J Pathol 149:1813-1822, 1996
27. Karjalainen JM, Eskelinen MJ, Kellokoski JK, et al: p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: Its relationship with p53, cell proliferation and survival. Br J Cancer 79:895-902, 1999
28. Bhoumik A, Ronai Z: ATF2: A transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7:2341-2345, 2008
29. Liu H, Deng X, Shyu YJ, et al: Mutual regulation of c-Jun and ATF2 by transcriptional activation and subcellular localization. Embo J 25:1058-1069, 2006
30. Bachmann IM, Straume O, Puntervoll HE, et al: Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606-8614, 2005
31. Maelandsmo GM, Holm R, Nesland JM, et al: Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 9:3383-3388, 2003
32. Banerji A, Das S, Chatterjee A: Culture of human A375 melanoma cells in the presence of fibronectin causes expression of MMP-9 and activation of MMP-2 in culture supernatants. J Environ Pathol Toxicol Oncol 27:135-145, 2008
33. Gaggioli C, Robert G, Bertolotto C, et al: Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol 127:400-410, 2007
34. Jaeger J, Koczan D, Thiesen HJ, et al: Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13:806-815, 2007
35. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
36. Väisänen A, Kallioinen M, Taskinen PJ, et al: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186:51-58, 1998
37. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T: Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 39:377-385, 2008
38. Rangel J, Nosrati M, Torabian S, et al: Osteopontin as a molecular prognostic marker for melanoma. Cancer 112:144-150, 2008
39. Pacifico MD, Grover R, Richman PI, et al: Development of a tissue array for primary melanoma with long-term follow-up: Discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115:367-375, 2005
40. Pearl RA, Pacifico MD, Richman PI, et al: Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: Implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg 61:265-271, 2008
41. Rangel J, Torabian S, Shaikh L, et al: Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24:4565-4569, 2006
42. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
43. Ascierto PA, Kirkwood JM: Adjuvant therapy of melanoma with interferon: Lessons of the past decade. J Transl Med 6:62, 2008